CN Patent

CN108135878A — 卡巴他赛及其治疗癌症的用途

Assigned to Aventis Pharma SA · Expires 2018-06-08 · 8y expired

What this patent protects

本发明涉及具有下式(I)的化合物，其可为碱形式或水合物或溶剂化物的形式，用于作为治疗具有肝损伤的患者中的癌症的药物的用途。

USPTO Abstract

本发明涉及具有下式(I)的化合物，其可为碱形式或水合物或溶剂化物的形式，用于作为治疗具有肝损伤的患者中的癌症的药物的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN108135878A
Jurisdiction
CN
Classification
—
Expires
2018-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.